Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Recovered from the drop as I guess investors don't want yo be caught with their pants doelwn when results are announce. Hope they are good and they should be with recent progress.
. Watch out for Simply Wall Street if you use it to guide investment. I do not think their analyst forecasts take into account the recent usa situation. In my opinion their analysis is out of date. I think their 'fair price' is up the creek!
Market was a bit slow reacting to such good news on 5th June. They have "got it" now.
Millions of ponds of shares have just been bought here. That's probably why it's been held down. Should see a TR1 notification soon. Follow the money.
Just listened to the investor presentation. Very encouraging.
Tristel ULT possesses numerous USP's over competitors, such as only needing 2mins contact time to disinfect versus 7mins with closest competitor.
Closest competitor sells a machine worth $10,000 that takes up space and needs to be replaced every 7 years while Tristel ULT doesn't require any upfront investment or space and is far more mobile and can be applied to a wider range of appliances.
They have a go to market deal where they will take royalties of sales so they will passively take in profit without any overheads so margin is essentially 100% on Tristel ULT income.
CEO said in his closing statement that although the company is already profitable, today's FDA approval will provide exponential growth for the company going forward.
It has been coming.Wish i had been able to buy more shares when sp feel to silly low valuation.
Been waiting for this a long LONG time. :))
Very much under the radar at the moment.
15% day rise here today now 425p
Only 18 posts here over 16 months .
5% spread.
Investor and analyst meeting called later today.
The door is open now to an absolutely massive market of which TSTL should take the majority. The huge increase in sales off the back of this high margin product should transform the company and it's SP.
News gets better and better.
FinnCap-
'We estimate the NPV of future royalty streams for Tristel ULT in the US to be worth c.£82m or 173p per share, with a range of 117-315p. We raise FY 2024 adjusted pre-tax profit by £0.8m (12%) to £7.6m, with adjusted EPS rising 6% to 12.3p (+23% growth on FY 2023), held back by a higher tax rate. We raise our target price to 500p.'
TRISTEL plc
("Tristel" or the "Company")
FDA De Novo approval
Tristel ULT approved by the FDA as a high level disinfectant for use on endocavity ultrasound probes and skin surface transducers
Tristel expects to gain significant market share in the world's largest ultrasound market
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products utilising proprietary chlorine dioxide technology, announces that the USA Food and Drug Administration ("FDA") has completed its review of the Company's De Novo request for classification (Class II) of Tristel ULT as a high level disinfectant, and has granted its approval for immediate sale.
Tristel DUO, the Company's intermediate level disinfectant approved by the USA Environmental Protection Agency for use on the ultrasound console and the non-invasive parts of the endocavity probe, is now registered in all states of the USA.
The Company estimates that over 215 million ultrasound scans are carried out in the United States annually. Approximately 20% of these scans require high level disinfection and the remainder require low or intermediate level disinfection. With the FDA approval, Tristel has two products approved in the USA that can meet the disinfection needs for all ultrasound scans. This is a unique competitive position.
The United States nationwide launch of Tristel ULT will commence in October this year, following Tristel DUO's market introduction late last year. The Company has already established a manufacturing base with Parker Laboratories Inc., New Jersey, and will utilise Parker's national distribution network for the ultrasound market. Parker is the largest supplier of ultrasound transmission gels in the USA. As both a gel and an appropriate disinfectant must be used in every ultrasound scan procedure, the combination of Tristel and Parker products promises a powerful combination.
Whilst Tristel is a new market entrant in the USA, the Company is very familiar with the competitive landscape which is almost identical in the other 40 plus countries in which Tristel operates. Approximately half of Tristel's global revenue is generated from the ultrasound market.
Further details of the Company's North American commercial strategy will be outlined to equity analysts and investors through a series of presentations over the next few weeks. Further details will be announced in due course.
Paul Swinney, Chief Executive of Tristel, said: "This FDA approval enables our full-blown entry into the United States ultrasound market and is a significant inflection point for the Company. We will now be present in the single largest ultrasound market in the world. This milestone achievement will allow us to significantly increase our global revenue along with our profit potential as we put Tristel's and Parker's resources behind Tristel ULT and DUO in the USA."
With H2 weighting - they will likely be a beat of forecast, i..e ahead of expec.
They do look expensive but could look really cheap at this level down the line bought some today because if fda approved goes through in June I doubt they will be this price again.
It won't wipe away the fall from almost 700p but I hope we can move up from here. I always reinvest the divi so the lowly SP is useful in that respect. USA angle will be useful to boost income. Hopefully no large sales on results from the dynamic duo as it really dents SP progress. Pretty good update!
Well done, Paul. Great results. Looking forward to return back to 400p+
Commenting on the interim results, Paul Swinney, Chief Executive of Tristel, said: "We are delighted to have increased sales by 16% on the first half of last year, above our long-term target for revenue growth.
In all regions the level of diagnostic examinations utilising our products is significantly higher than before the commencement of the pandemic.
We have now entered the North American market, having launched Duo Ophthalmology in Canada, and Duo Ultrasound in the USA under our EPA approval, and expect the FDA's decision on our De Novo submission in June.
The growth prospects for the Group are stronger than ever and we look to the future with confidence."
https://www.londonstockexchange.com/news-article/TSTL/half-year-report/15843025
Look decent to me and reads well.
Still expensive
Lowest SP for 3 years with results around the corner.
The meticulous Maynard Paton scrutinises TSTL
Excellent read
https://maynardpaton.com/2023/01/12/tristel-pandemic-disrupted-fy-2022-reiterates-reassuring-10-15-year-sales-growth-ambition-as-us-regulatory-approval-now-relies-upon-fda-negotiation-over-product-batches/
Good news today. 11 months more and a very significant market becomes fully open with a high barrier to entry. Hopefully will rerate as we move closer to getting approval.